FN-1501 manufacturers
- FN-1501
-
- $84.00
-
2026-07-27
- CAS:1429515-59-2
- Purity: 97.40%
- Supply Ability: 10g
|
| | FN-1501 Basic information |
| Product Name: | FN-1501 | | Synonyms: | 1H-Pyrazole-3-carboxamide, N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-;4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide;FN-1501, 10 mM in DMSO | | CAS: | 1429515-59-2 | | MF: | C22H25N9O | | MW: | 431.49 | | EINECS: | | | Product Categories: | | | Mol File: | 1429515-59-2.mol |  |
| | FN-1501 Chemical Properties |
| density | 1.427±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : ≥ 50 mg/mL (115.88 mM) | | form | Solid | | pka | 11.73±0.70(Predicted) | | color | White to off-white |
| | FN-1501 Usage And Synthesis |
| Uses | FN-1501 is a potent inhibitor of FLT3 and CDK, with IC50s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity. | | in vivo | FN-1501 exhibits potent antitumor activity, and shows little cytotoxicity on normal lymphocyte cells, with LD50 of 185.67 mg/kg in ICR mice. FN-1501 (15. 30, or 40 mg/kg/d, i.v.) dose-dependently and significantly suppresses the growth of tumor in MV4-11-cell-inoculated-xenograft mice[1]. | | IC 50 | Cdk4/cyclin D1: 0.85 nM (IC50); CDK6/cyclinD1: 1.96 nM (IC50); cdk2/cyclin A: 2.47 nM (IC50); FLT3: 0.28 nM (IC50) | | References | [1] Wang Y, et al. Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518. DOI:10.1021/acs.jmedchem.7b01261 |
| | FN-1501 Preparation Products And Raw materials |
|